Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2018)
22 slides from Adalta's shareholder meeting presentation, Nov 28, 2018
Slide 1: AdAlta Investor Presentation AGM 2018
For personal use only AdAlta Investor Presentation AGM 2018 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) [email protected]
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta 2018 AGM Agenda
ADALTA 2018 AGM AGENDA For personal use only Chairman introduction AGM formal proceedings CEO presentation 3
Slide 4: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary For personal use only AdAlta Limited (ASX:1AD) is an Australian listed drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i- bodies, for treating a wide range of human disea
Slide 5: Financial position
Financial position For personal use only Key financial details Share performance (last 12 months) 12-month Share Price Performance ASX code 1AD 0.40 1.0 Share price (27 November 2018) AU$0.26 0.36 0.8 Market capitalisation AU$30.44m Share Price ($) Volume (’000) Shares on issue* 117,082,073 0.32 0.6
Slide 6: Management team in place to deliver strategy
Management team in place to deliver For personal use only strategy Sam Cobb Founding CEO and Managing Director Extensive experience in raising equity, contract and grant funding. 15 years of commercialisation and management experience. Mick Foley, PhD Chief Scientific Officer Founding scientist of A
Slide 7: Extensive support from institutional investors and HNWs
Extensive support from institutional investors For personal use only and HNWs Top 20 shareholders ~80% Australian based venture capital $40m 60% institutional shareholders fund 11% HNWs with >500K shares each $27b under management, global 4% founding academic institutions equities investor 2.6% Boar
Slide 8: AD-214, a superior drug candidate
AD-214, a superior drug candidate For personal use only AdAlta’s lead i-body AD-214 is an Fc-Fusion 8
Slide 9: AD-214 has broad application in treating fibrosis
AD-214 has broad application in treating fibrosis For personal use only AdAlta data shows that AD-214 can improve fibrosis across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis EYE: Wet Age Related Macular Degeneration Lung Eye Liver LIVER: NASH IPF Wet-AMD & PVR NASH & CIRRHOSIS S
Slide 10: Developing the manufacturing process for AD-214
Developing the manufacturing process for For personal use only AD-214 Process Optimisation Cell Line Cell Line Purification Formulation Development Expression Process Parameters such The components Several techniques as pH, oxygen, that make up the DNA is are evaluated to temperature, AD-214 introdu
Slide 11: AD-214 manufacturing progress
AD-214 manufacturing progress For personal use only Process Optimisation Cell Line Cell Line Purification Formulation Development Expression Process Commenced Commenced Commenced Commenced June 2018 October 2018 October 2018 October 2018 Initial results of Expected Expected Expected 1g/L achieved co
Slide 12: Manufacturing Milestones
Manufacturing Milestones For personal use only Milestone Expected Date October 2018 ✓ Cell line development Initial results just over 1g/L Optimisation of Process March 2019 development AD-214 material available for May 2019 toxicity studies AD-214 material available for December 2019 Phase I clinic
Slide 13: AD-214 development: key milestones
AD-214 development: key milestones For personal use only 2018 2019 2020 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Manufacturing Dosing and PK Toxicology Partnering of lead studies studies candidate based on other Phase I benchmark deals Publication of data Development of i-body pipeline BD and partnerships 13
Slide 14: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments For personal use only Fibrosis assets acquired at an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-18 Samumed SM04646 United $10m upfront, plus Undergoing Phase I, USA rights Therape
Slide 15: Significant achievements last months
Significant achievements last 12 months For personal use only ✓ Redesign of AD-114 to AD-214, with improved potency and half life ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; stre
Slide 16: Some of our FY18 media and analyst coverage
Some of our FY18 media and analyst coverage For personal use only “Watch out CSL, here we “Here’s a bunch of top ASX respiratory come': biotech gears to go stocks that will leave you breathless” global” “AdAlta Enhances Its Lead” “Smaller, smarter antibody-like drugs” “Pivot to superior lead candida
Slide 17: Financial operating results
Financial operating results For personal use only The Company reported a loss for the year ended 30 June 2018, after accounting for income tax benefit, of ($3,854,894) (30 June 2017: ($2,832,517)). The Company remains in a solid cash position with ~$5.74 million cash in the bank as at 30 September 2
Slide 18: AdAlta business model – strategy to create value
AdAlta business model – strategy to For personal use only create value Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & i-bodies new royalties technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 19: Market benchmarks
Market benchmarks For personal use only Fibrosis Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS lead AD-214 $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen ir ed u April-16 with Abbvie May -17 with AZ cq A with San
Slide 20: Expected news flow
Expected news flow For personal use only H1 2018 ✓ Publication of AD-114 data in Scientific Reports demonstrating i-body application of pulmonary fibrosis with human tissue and animal model data ✓ Investor and analyst briefing detailing application of the i-body for the undruggable targets such as G
Slide 21: AdAlta Limited (ASX: 1AD) summary
AdAlta Limited (ASX: 1AD) summary For personal use only Successfully raised $4.73m in Placement with institutional and high net worth investors and SPP with existing shareholders, completed post quarter’s end, securing funding for AD-214 to end of manufacturing September cash position of $5.74m, wit
Slide 22: Contact us
For personal use only Contact us: Sam Cobb, CEO [email protected] www.adalta.com.au 22